Abstract CT052: A phase IB study of mRNA-based active cancer vaccine, BI1361849, combined with durvalumab and tremelimumab immunotherapy in patients with non-small cell lung cancer (NSCLC)
Dung‐Tsa Chen(Moffitt Cancer Center), Jhanelle E. Gray(Moffitt Cancer Center), Toni Ricciardi(Ludwig Cancer Research), Zachary Thompson(Moffitt Cancer Center), Tawee Tanvetyanon(Moffitt Cancer Center), Hirva Mamdani(Wayne State University), Joshua K. Sabari(NYU Langone Health), Jonathan R. Thompson, Jiaxin Niu(The University of Texas MD Anderson Cancer Center), Aileen Ryan(Ludwig Cancer Research), Thanmai Posina(Moffitt Cancer Center), Ram Thapa(Moffitt Cancer Center), Kristen Aufiero Ramirez(Ludwig Cancer Research), Ralph Venhaus(Ludwig Cancer Research)
Cited by 6
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
|Journal of the National Comprehensive Cancer Network|2023|480
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373